Faculty, Staff and Student Publications
Publication Date
4-28-2022
Journal
Nature Communications
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerged as an attractive therapeutic target. UCART123 is an investigational product consisting of allogeneic T cells expressing an anti-CD123 chimeric antigen receptor (CAR), edited with TALEN
Keywords
Acute Disease, Animals, Dendritic Cells, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Interleukin-3 Receptor alpha Subunit, Mice, Myeloproliferative Disorders, Skin Neoplasms, Acute lymphocytic leukaemia, Cell therapies, Haematological cancer
DOI
10.1038/s41467-022-29669-8
PMID
35484100
PMCID
PMC9051102
PubMedCentral® Posted Date
4-28-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Hematology Commons, Medical Sciences Commons, Neoplasms Commons, Oncology Commons